Clinical trials: Antimicrobial Susceptibility Testing
Bacteremia, Fungemia
Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture
The "Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification \& Antimicrobial Susceptibility Testing" is designed to validate the clinical performance of the Accelerate ID/AST…
- Trial name
- NCT02719769
- Where
- 14 sites in United States
- Volunteers
- 4,009 people
- Sponsor
- Accelerate Diagnostics, Inc.
Gram-negative Bacteremia, Bloodstream Infection
Fast Antibiotic Susceptibility Testing for Gram Negative Bacteremia Trial
This study is a 2-arm, multicenter, multinational, prospective, randomized, controlled clinical trial. Hospitalized subjects with blood cultures growing Gram negative bacilli (GNB) will be randomized 1:1 to have the positive…
- Trial name
- FAST (NCT06174649)
- Testing
- Reveal
- Where
- 7 sites in Greece, India and 2 more
- Volunteers
- 899 people
- Sponsor
- Duke University
Hematologic Diseases, Bacteremia Sepsis
Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases
The purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (dRAST), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with…
- Trial name
- NCT03611257
- Testing
- dRAST, Current standard method
- Where
- South Korea
- Volunteers
- 116 people
- Sponsor
- Seoul National University Hospital
Infection
Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns
EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites). Objectives: Comparison of antimicrobial susceptibility using disc-diffusion method Assessing prevalence of…
- Trial name
- EGAST 2008 (NCT00728624)
- Where
- 12 sites in India
- Volunteers
- 2,039 people
- Sponsor
- Pfizer
Gram-negative Bacteremia
Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia
RAPIDS-GN is a multi-center, prospective, randomized, controlled trial to evaluate the following strategies for patients with confirmed gram-negative bacillus bacteremia (GNB): 1.
- Trial name
- RAPIDS-GN (NCT03218397)
- Testing
- Accelerate PhenoTest™ BC Kit, Standard Culture and AST
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- Duke University
Bacteremia
Rapid Antimicrobial Susceptibility Testing with MIC Directly from Positive Blood Cultures with ASTar
The investigators want to investigate the clinical impact of early antimicrobial susceptibility results for gram negative bacilli isolated from blood cultures on antimicrobial choices and early switches of antimicrobial therapy.
- Trial name
- RASTA (NCT06218277)
- Testing
- ASTAR
- Where
- Belgium
- Volunteers
- 80 people
- Sponsor
- University Hospital, Ghent
Bacteremia
Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates
This is a performance and reproducibility study to validate new or updated antimicrobials on the Accelerate PhenoTest™ BC kit. The data from this study will be used to support the submission to the FDA for clearance in the US and…
- Trial name
- NCT04295915
- Testing
- Specimens that meet inclusion criteria
- Where
- 3 sites in United States
- Volunteers
- 731 people, healthy volunteers welcome
- Sponsor
- Accelerate Diagnostics, Inc.
Sepsis With Escherichia Coli
Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings
This study aims at determining within a short time (<3h) the susceptibility to clinical isolates of E. coli to the major antibiotics directly from positive blood cultures.
- Trial name
- MALDI-TRAc (NCT02860247)
- Volunteers
- 103 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Sepsis
Evaluation of the Performance of the IDBIORIV Method in Pathogen Identification and Antibiotic Susceptibility Testing in Patients With Sepsis
Sepsis is a disruption of homeostasis in the human body in response to bloodstream infection and is associated with a high risk of mortality.
- Trial name
- IDBIORIV (NCT06219135)
- Testing
- no intervention - Contamination group, blood sample - Bacteraemia group, no intervention - Emergency group
- Where
- 23 sites in France
- Volunteers
- 1,372 people
- Sponsor
- Hospices Civils de Lyon
Cystic Fibrosis, Chronic Bronchitis
Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)
This was a randomized multi-center clinical trial to compare the microbiological efficacy, clinical efficacy, and safety of using standard versus biofilm susceptibility testing of P.
- Trial name
- NCT00153634
- Testing
- IV amikacin, PO azithromycin, IV ceftazidime
- Where
- 8 sites in United States
- Volunteers
- 75 people
- Sponsor
- Seattle Children's Hospital
Cystic Fibrosis
Use of a Biofilm Antimicrobial Susceptibility Assay to Guide Antibiotic Therapy
The purpose of this study is to determine whether choosing antibiotics based on a biofilm antimicrobial susceptibility assay rather than a conventional planktonic antimicrobial susceptibility assay to treat CF patients with…
- Trial name
- NCT00786513
- Testing
- Conventional antimicrobial susceptibility testing, Biofilm antimicrobial susceptibility testing
- Where
- 5 sites in Canada
- Volunteers
- 134 people
- Sponsor
- The Hospital for Sick Children